Have a feature idea you'd love to see implemented?
Let us know!
TCRX TScan Therapeutics Inc
Price (delayed)
$3.94
Market cap
$210.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.96
Enterprise value
$162.49M
Highlights
The EPS has soared by 61% YoY
TScan Therapeutics's quick ratio has increased by 45% YoY and by 23% QoQ
The equity has grown by 36% YoY but it has contracted by 10% from the previous quarter
TCRX's gross profit is down by 45% YoY and by 23% from the previous quarter
TScan Therapeutics's revenue has decreased by 45% YoY and by 23% QoQ
Key stats
What are the main financial stats of TCRX
Market
Valuations
Earnings
Shares outstanding
53.37M
Market cap
$210.28M
Enterprise value
$162.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.91
Price to sales (P/S)
49.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.36
Revenue
$9.36M
EBIT
-$107.58M
EBITDA
-$102.91M
Free cash flow
-$110.58M
Per share
Balance sheet
Liquidity
EPS
-$0.96
Free cash flow per share
-$0.93
Book value per share
$4.32
Revenue per share
$0.08
TBVPS
$2.93
Total assets
$348.03M
Total liabilities
$118.94M
Debt
$90.36M
Equity
$229.09M
Working capital
$245.43M
Debt to equity
0.39
Current ratio
9.56
Quick ratio
9.64
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
-1,099.2%
Gross margin
100%
Net margin
-1,188.9%
Operating margin
-1,276.1%
Return on assets
-36%
Return on equity
-58.7%
Return on invested capital
-53.5%
Return on capital employed
-33.7%
Return on sales
-1,149.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TCRX stock price
How has the TScan Therapeutics stock price performed over time
Intraday
-4.37%
1 week
-18.26%
1 month
-25.24%
1 year
-5.74%
YTD
-32.42%
QTD
-20.88%
Financial performance
How have TScan Therapeutics's revenue and profit performed over time
Revenue
$9.36M
Gross profit
$9.36M
Operating income
-$119.47M
Net income
-$111.3M
Gross margin
100%
Net margin
-1,188.9%
The operating margin has plunged by 138% YoY and by 40% from the previous quarter
TScan Therapeutics's net margin has shrunk by 128% YoY and by 39% QoQ
TCRX's gross profit is down by 45% YoY and by 23% from the previous quarter
TScan Therapeutics's revenue has decreased by 45% YoY and by 23% QoQ
Growth
What is TScan Therapeutics's growth rate over time
Valuation
What is TScan Therapeutics stock price valuation
P/E
N/A
P/B
0.91
P/S
49.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.36
The EPS has soared by 61% YoY
The price to book (P/B) is 49% lower than the last 4 quarters average of 1.8
The equity has grown by 36% YoY but it has contracted by 10% from the previous quarter
TScan Therapeutics's revenue has decreased by 45% YoY and by 23% QoQ
The price to sales (P/S) is 7% higher than the last 4 quarters average of 46.6
Efficiency
How efficient is TScan Therapeutics business performance
The ROS has shrunk by 130% YoY and by 39% QoQ
TScan Therapeutics's ROE has increased by 11% YoY
TScan Therapeutics's ROIC has increased by 4.8% from the previous quarter
Dividends
What is TCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TCRX.
Financial health
How did TScan Therapeutics financials performed over time
The total assets is 193% greater than the total liabilities
TCRX's current ratio is up by 46% year-on-year and by 23% since the previous quarter
TScan Therapeutics's quick ratio has increased by 45% YoY and by 23% QoQ
TScan Therapeutics's debt is 61% lower than its equity
The equity has grown by 36% YoY but it has contracted by 10% from the previous quarter
The debt to equity has declined by 24% year-on-year but it has increased by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.